Toro 18 Holdings LLC, a part of a group that previously held a significant stake in Universal Electronics Inc. (), recently sold common stock totaling approximately $602,774. These transactions took place on September 10 and September 11, 2026. On September 10, Toro 18
Claudia Hughes, SVP & Chief Sales Officer at Global Industrial Co. (NASDAQ:GIC), recently acquired company stock totaling $3,966 through a series of transactions. The purchases occurred at prices ranging from $22.39 to $38.67 per share. The transactions, classified
Robert Ramsey Hamady, Chief Financial Officer of NuScale Power Corp (), reported recent transactions involving the company’s Class A Common Stock. On August 17, 2026, Mr. Hamady sold 20,000 shares, generating a total value of $189,800 at a price
Milton C. Ault III, Executive Chairman of Hyperscale Data, Inc. (), recently purchased $33,651 worth of the company’s Class A Common Stock. The transactions occurred over three days in September 2026, with prices ranging from $0.1857 to $0.1892 per
Daniel Antonio Perez, CEO and Co-Founder of Hinge Health, Inc. (), along with his spouse, disposed of Class A Common Stock totaling approximately $22.3 million on September 10, 2026. These transactions were executed pursuant to a Rule 10b5-1
Raymond John W, a director and special advisor at IonQ, Inc. (), sold 2,407 shares of the company’s common stock on September 10, 2026. The shares were sold at a price of $37.21 per share, resulting in a total
Alpha Compute Corp. () Chief Financial Officer Wesley Allen Levitt recently acquired shares in the company, according to a new SEC filing. On September 9, 2026, Mr. Levitt purchased 1,000 ordinary shares at a price of $5.0955 per share, totaling $5,095.
Bracebridge H. Young Jr., a director at Fold Holdings, Inc. (), recently purchased shares of the company’s common stock totaling $11,049. The transactions occurred on September 11, 2026. Mr. Young acquired a total of 20,000 shares through two separate
George Kurtz, President and CEO of CrowdStrike Holdings, Inc. (), sold 20,000 shares of the company’s Class A common stock for a total value of $4,191,076. The transactions occurred on September 9 and September 10, 2026, with sale prices ranging
Robin Shane Readnour, a director at AN2 Therapeutics, Inc. (), sold shares totaling $6,674 on September 9, 2026. The sales occurred at prices ranging from $6.02 to $6.04 per share. The timing is notable as the stock has declined 8.2% over the
